{Reference Type}: Journal Article
{Title}: Insertion of I-125 seed-loaded stent for inoperable hilar cholangiocarcinoma.
{Author}: Gao FL;Wang Y;Lu J;Zhu GY;Huang XZ;Ren DQ;Guo JH;
{Journal}: Wideochir Inne Tech Maloinwazyjne
{Volume}: 16
{Issue}: 4
{Year}: Dec 2021
{Factor}: 1.627
{DOI}: 10.5114/wiitm.2021.105530
{Abstract}: <B>BACKGROUND: </B>Stent insertion is the most frequently used option to treat malignant biliary obstruction (MBO) patients. Hilar cholangiocarcinoma (HCCA) is the most common disease that causes hilar MBO.<BR><B>OBJECTIVE: </B>To assess the clinical efficacy and long-term outcomes of I-125 seed-loaded stent (ISS) insertion for HCCA patients.<BR><B>METHODS: </B>Consecutive patients with HCCA underwent either normal stent (NS) or ISS insertion between January 2017 and December 2019. The baseline and treatment data of these two groups were compared.<BR><B>RESULTS: </B>During the period, a total of 93 patients with inoperable HCCA were divided into either NS (n = 48) or ISS (n = 45) insertion groups at our centre. Technical success rates of the NS and ISS insertion were 91.7% and 95.6%, respectively (p = 0.733). Clinical success rates were 93.2% and 100% in the NS and ISS groups, respectively (p = 0.24). Stent dysfunction was observed in 11 and 8 patients in the NS and ISS groups, respectively (p = 0.47). The median stent patency was 143 days and 208 days in the NS and ISS groups, respectively (p < 0.001). All patients died in the follow-up period, with median survival duration of 178 days and 220 days in the NS and ISS groups, respectively (p < 0.001). ISS insertion was the only predictor of longer patency (p = 0.002) and survival (p = 0.01).<BR><B>CONCLUSIONS: </B>ISS insertion might achieve longer patency and overall survival in patients with inoperable HCCA as compared with NS insertion.